Differential Functions of ERK1 and ERK2 in Lung Metastasis Processes in Triple-Negative Breast Cancer

Investigators provided evidence supporting the notion that ERK1 and ERK2 have functionally distinct properties and that ERK2, not ERK1, primarily contributed to lung metastasis in a riple negative breast cancer mouse model.
[Scientific Reports]
Abstract
Bookmark

No account yet? Register

0
Share

BH3 Mimetics Selectively Eliminate Chemotherapy-Induced Senescent Cells and Improve Response in TP53 Wild-Type Breast Cancer

Researchers showed that ABT-263, a BH3 mimetic that targets antiapoptotic proteins BCL2/BCL-XL/BCL-W, had no effect on proliferating cells, but rapidly and selectively induced apoptosis in a subset of chemotherapy-treated cancer cells, though sensitivity required days to develop.
[Cell Death and Differentiation]
Full Article
Bookmark

No account yet? Register

0
Share

Opposing Functions of BRD4 Isoforms in Breast Cancer

Investigators showed, by isoform-specific knockdown and endogenous protein detection, along with transgene expression, the less abundant bromodomain-containing protein 4 short isoform was oncogenic while bromodomain-containing protein 4 long isoform was tumor-suppressive in breast cancer cell proliferation and migration, as well as mammary tumor formation and metastasis.
[Molecular Cell]
AbstractGraphical Abstract
Bookmark

No account yet? Register

0
Share

SRPK1 Acetylation Modulates Alternative Splicing to Regulate Cisplatin Resistance in Breast Cancer Cells

The authors identified that Tip60-mediated acetylation of serine-arginine protein kinase 1(SRPK1) was closely associated with chemotherapy sensitivity.
[Communications Biology]
Full Article
Bookmark

No account yet? Register

0
Share

Destabilization of β-Catenin and RAS by Targeting the Wnt/β-Catenin Pathway as a Potential Treatment for Triple-Negative Breast Cancer

Scientists found that both β-catenin and RAS, as well as epidermal growth factor receptor, were overexpressed and correlated with one another in tumor tissues of TNBC patients.
[Experimental and Molecular Medicine]
Full Article
Bookmark

No account yet? Register

0
Share

Pregnancy Reprograms the Epigenome of Mammary Epithelial Cells and Blocks the Development of Premalignant Lesions

The authors investigated how pregnancy reprogrammed enhancer chromatin in the mammary epithelium of mice and influenced the transcriptional output of the oncogenic transcription factor cMYC.
[Nature Communications]
Full Article
Bookmark

No account yet? Register

0
Share

Combined PARP and ATR Inhibition Potentiates Genome Instability and Cell Death in ATM-Deficient Cancer Cells

Scientists showed that olaparib combined synergistically with the synergistically with the ataxia-telangiectasia mutated and Rad3-related-inhibitor AZD6738, in vitro, leading to selective cell death in cell death in ataxia-telangiectasia mutated-deficient cells.
[Oncogene]
Full Article
Bookmark

No account yet? Register

0
Share

DNMT1: A Key Drug Target in Triple-Negative Breast Cancer

The author presents and discusses the oncogenic functions rendered by DNA methyltransferase 1 (DNMT1) in triple negative breast cancer, and DNMT1 inhibitors targeting TNBC cells.
[Seminars in Cancer Biology]
Abstract
Bookmark

No account yet? Register

0
Share

ECOG-ACRIN Provides Syndax Pharmaceuticals With Results of Phase III E2112 Trial of Entinostat Plus Exemestane in Patients with HR+, HER2 Breast Cancer

Syndax Pharmaceuticals, Inc. announced receipt of the final results of E2112, that evaluated the investigational compound entinostat, Syndax’s class I HDAC inhibitor, plus exemestane in patients with advanced hormone receptor positive, human epidermal growth factor receptor 2 negative breast cancer who have progressed on a non-steroidal aromatase inhibitor.
[Syndax]
Press Release
Bookmark

No account yet? Register

0
Share

Daiichi Sankyo Launches ENHERTU® in Japan for Patients with HER2 Positive Unresectable or Metastatic Breast Cancer

Daiichi Sankyo Company, Limited announced the launch of ENHERTU® (trastuzumab deruxtecan), a HER2 directed antibody drug conjugate, in Japan for the treatment of patients with HER2 positive unresectable or recurrent breast cancer after prior chemotherapy.
[Daiichi-Sankyo]
Press Release
Bookmark

No account yet? Register

0
Share
Share